I
01541
ImmuneOnco Biopharmaceuticals (S…
11.01
-0.48-4.18%Closed16:08 09/02 HKT
OPEN/PREV CLOSE11.490/11.490
TODAY RANGE10.810-11.650
VOL1.68M
MARKET CAP4.48B
52 WEEK RANGE3.210-15.660
AVG VOL (3M)3.76M
% TURNOVER0.41%
TURNOVER18.72M
P/E (TTM)-13.511
% RANGE7.31%
EPS(TTM)-0.815
P/E(FORWARD)-11.994
P/B7.650
BVPS1.439
DIVIDEND--
P/S36.481
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP4.36B
SHARES OUTSTANDING407.31M
NEXT EARNINGS--
FREE FLOAT396.28M
LOT SIZE200
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·4d ago
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) 9.3% loss last week hit both individual investors who own 46% as well as institutions
Simply Wall St·07/11 22:13
Risks Still Elevated At These Prices As ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) Shares Dive 29%
Simply Wall St·06/27 22:51
ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Is Using Debt Safely
Simply Wall St·05/23 00:25
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) 77% Share Price Surge Not Quite Adding Up
Reuters·05/22 10:20
INSTIL BIO INC - US PHASE 1B/2 TRIAL OF '2510 TO START BEFORE END OF 2025
Simply Wall St·05/01 06:21
ImmuneOnco Biopharmaceuticals (Shanghai) Full Year 2024 Earnings: CN¥0.84 loss per share (vs CN¥1.05 loss in FY 2023)
Simply Wall St·04/30 06:19
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) market cap touched HK$2.5b last week, benefiting both retail investors who own 32% as well as institutions
Simply Wall St·04/03 22:42
Founder of ImmuneOnco Biopharmaceuticals (Shanghai) Tian Wenzhi Buys More Stock
Simply Wall St·04/01 22:26
Why Investors Shouldn't Be Surprised By ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) 27% Share Price Surge
Simply Wall St·03/26 23:14
ImmuneOnco Biopharmaceuticals (Shanghai) Full Year 2024 Earnings: CN¥0.84 loss per share (vs CN¥1.05 loss in FY 2023)
Simply Wall St·03/26 23:10
Here's Why ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Can Manage Its Debt Despite Losing Money
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.